Annexin Pharmaceuticals AB (publ) (FRA:Q910)

Market Cap	6.07M -63.6%
Revenue (ttm)	n/a
Net Income	-3.71M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,088
Open	0.6880
Previous Close	0.7360
Day's Range	0.6880 - 0.6880
52-Week Range	0.6880 - 2.5200
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About FRA:Q910

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: Q910

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error